Atlas Trials

G D Searle

3 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch G D Searle

RecordFirmDate
Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3 (NCT00001993)G D Searle
Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible) (NCT00002079)G D Searle
Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex (NCT00000692)G D Searle

Track G D Searle automatically

Every clearance here is in the API, with alerts when new ones post.